FDA pushed to be more open, collaborative to accelerate rare disease R&D
FDA urged to collaborate with EMA (European Medicines Agency) to accelerate rare disease drug approvals: A report by the National Academies of Sciences, Engineering and Medicine recommends that the FDA enhance transparency and collaborate with the European Medicines Agency to systematically review past rare disease drug applications and regulatory decision-making to expedite approvals. The report advises the EMA and FDA to create a continuously updated public database for these results, and also recommends Congress remove the Pediatric Research Equity Act orphan exemption.